Abstract: Modifying vehicle display parameters using operator gaze, including: detecting a gaze of an operator of a vehicle; and modifying one or more parameters of a display based on the gaze of the operator.

Abstract: Blended operator and autonomous control in an autonomous vehicle, including: receiving sensor data from a plurality of sensors of an autonomous vehicle; determining, based on the sensor data, a degree of autonomous control for each control input of a plurality of control inputs; and applying the degree of autonomous control for each control input of the plurality of control inputs.

Abstract: Modifying vehicle display parameters using operator gaze, including: detecting a gaze of an operator of a vehicle; and modifying one or more parameters of a display based on the gaze of the operator.

Abstract: Automatically adjusting ergonomic factors of a vehicle seat, including: receiving first video data capturing a person outside of a vehicle; identifying, based on the first video data, one or more physical attributes of the person; and modifying vehicle seat configuration based on the one or more physical attributes.

Abstract: Anticipatory vehicle electronic control unit (ECU) actuation, including: determining, based on sensor data capturing an environment around a vehicle, a predicted environmental state corresponding to a future time and comprising a transition in exterior lighting; determining, based on the predicted environmental state, an actuation state for one or more headlights of the vehicle; and configuring the one or more headlights of the vehicle according to the actuation state before the future time.

Abstract: Automated occupant protection in stationary vehicles, including: detecting that an occupant is inside a stationary vehicle and that an operator is not in the stationary vehicle; detecting, based on one or more observations of the occupant, that one or more risk conditions have been met; and sending an alert to the operator in response to the one or more risk conditions being satisfied.

Abstract: Automatic disengagement of an autonomous driving mode may include receiving, from a steering torque sensor, torque sensor data indicating an amount of torque applied to a steering system of the autonomous vehicle; determining a predicted torque based on one or more motion attributes of the steering system of the autonomous vehicle; determining a differential between the predicted torque and the amount of torque; and determining, based on the differential, whether to disengage an autonomous driving mode of the autonomous vehicle.

Abstract: Detecting operator contact with a steering wheel, including: applying a torque to at least a portion of a steering system of an autonomous vehicle; identifying a measured torque for a steering wheel of the autonomous vehicle; calculating, based on the applied torque, an expected torque for the steering wheel; and determining, based on a difference between the measured torque and the expected torque, whether an operator of the autonomous vehicle is in contact with the steering wheel.

Abstract: Blended operator and autonomous control in an autonomous vehicle, including: receiving sensor data from a plurality of sensors of an autonomous vehicle; determining, based on the sensor data, a degree of autonomous control for each control input of a plurality of control inputs; and applying the degree of autonomous control for each control input of the plurality of control inputs.

Abstract: The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (IFN-?) by expressing indolamine-2,3-dioxygenase (IDO) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues.

Abstract: The blood half-life of endogenous peptides such as somatostatin and cortistatin is extremely short, barely reaching a few In minutes [Skamene et al., Clin. Endocrinol. 1984, 20, 555-564]. Thus, there is a need to find new systems or compositions that comprise cortistatinor an analogue thereof for the treatment of those pathologies in which specific cortistatin receptors and those receptors shared with other molecules like somatostatin (sstr1, sstr2, sstr3, sstr4 and/or sstr5) and/or ghrelin (GHSR) are expressed, being, furthermore, more stable in blood than cortistatin. The present invention providesan improved means for providing cortistatinor an analogue thereof as a pharmaceutically active agent in latent form, more stable in blood than cortistatin that liberates cortistatin in a controlled-release manner.

Abstract: Automatic disengagement of an autonomous driving mode may include receiving, from a steering torque sensor, torque sensor data indicating an amount of torque applied to a steering system of the autonomous vehicle; determining a predicted torque based on one or more motion attributes of the steering system of the autonomous vehicle; determining a differential between the predicted torque and the amount of torque; and determining, based on the differential, whether to disengage an autonomous driving mode of the autonomous vehicle.

Abstract: The invention relates to the use of mesenchymal stem cells (MSCs) for treating systemic inflammatory response syndrome (SIRS) in a subject. The invention provides compositions, uses and methods for the treatment of SIRS.

Abstract: The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (IFN-?) by expressing indolamine-2,3-dioxygenase (IDO) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues.

Abstract: The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (IFN-?) by expressing indolamine-2,3-dioxygenase (IDO) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues.

Abstract: The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (IFN-?) by expressing indolamine-2,3-dioxygenase (IDO) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues.

Abstract: The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (IFN-?) by expressing indolamine-2,3-dioxygenase (IDO) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues.

Abstract: The invention relates to the use of mesenchymal stem cells (MSCs) for treating systemic inflammatory response syndrome (SIRS) in a subject. The invention provides compositions, uses and methods for the treatment of SIRS.

Abstract: The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (IFN-?) by expressing indolamine-2,3-dioxygenase (IDO) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues.

Abstract: A pharmaceutical composition for the treatment and/or prevention of septic shock has VPAC1, VPAC2 or PAC1 receptor agonist combined with a pharmaceutically acceptable carrier. A method for treating or preventing septic shock is provided as well in which a therapeutically effective amount of the pharmaceutical composition is administered to a patient.